Skip to main content
. 2022 Sep 13;13:998620. doi: 10.3389/fimmu.2022.998620

Figure 5.

Figure 5

Subgroup analysis of pCR rate in patients receiving nICT. nICT, neoadjuvant immune checkpoint inhibitor in combination with chemotherapy; PC/TP, paclitaxel plus carboplatin or cisplatin.